TY - JOUR
T1 - Loss of p16 and/or pRb protein expression in NSCLC
T2 - An immunohistochemical and prognostic study
AU - Chen, Jung Ta
AU - Chen, Yi Chun
AU - Chen, Chih Yi
AU - Wang, Yi Ching
N1 - Funding Information:
We are grateful to Professor Ming-Chei Maa for her critical revision of this manuscript. This work was supported in part by Grant DOH87-HR-611 from the National Health Research Institute, Department of Health, The Executive Yuan, and by Grant NSC 89-2318-B-003-002-M51 from the National Science Council, The Executive Yuan, Republic of China.
PY - 2001
Y1 - 2001
N2 - The disruption of p16/pRb pathway has been reported in several types of human cancer including lung cancer. However, the etiological and prognostic involvement of this pathway remains poorly defined in lung tumorigenesis in Taiwan. Therefore, we investigated the expressions of p16 and pRb in 107 non-small cell lung cancer (NSCLC) patients by immunohistochemical analysis. The associations of altered p16 and pRb expressions with prognosis were also examined. Sixty-four specimens (59.8%) exhibited alteration of p16 and/or pRb expression, with 49.5 and 22.4% of the tumors failing to express p16 and pRb, respectively. However, there was no reciprocally correlated expression of p16 and pRb. Negative p16 and pRb expression did not correlate well with patients' clinicopathological parameters such as age, sex, smoking habit, tumor type, and tumor stage. In addition, negative p16 and pRb expression was not statistically associated with poor prognosis (P=0.10 and P=0.74, respectively). Our results suggested that the disruption of the p16/pRb pathway plays a significant role in NSCLC tumorigenesis whereas it may not have significant importance in the prognostic evaluation of NSCLC in Taiwan.
AB - The disruption of p16/pRb pathway has been reported in several types of human cancer including lung cancer. However, the etiological and prognostic involvement of this pathway remains poorly defined in lung tumorigenesis in Taiwan. Therefore, we investigated the expressions of p16 and pRb in 107 non-small cell lung cancer (NSCLC) patients by immunohistochemical analysis. The associations of altered p16 and pRb expressions with prognosis were also examined. Sixty-four specimens (59.8%) exhibited alteration of p16 and/or pRb expression, with 49.5 and 22.4% of the tumors failing to express p16 and pRb, respectively. However, there was no reciprocally correlated expression of p16 and pRb. Negative p16 and pRb expression did not correlate well with patients' clinicopathological parameters such as age, sex, smoking habit, tumor type, and tumor stage. In addition, negative p16 and pRb expression was not statistically associated with poor prognosis (P=0.10 and P=0.74, respectively). Our results suggested that the disruption of the p16/pRb pathway plays a significant role in NSCLC tumorigenesis whereas it may not have significant importance in the prognostic evaluation of NSCLC in Taiwan.
UR - http://www.scopus.com/inward/record.url?scp=0035144783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035144783&partnerID=8YFLogxK
U2 - 10.1016/S0169-5002(00)00191-4
DO - 10.1016/S0169-5002(00)00191-4
M3 - Article
C2 - 11165395
AN - SCOPUS:0035144783
SN - 0169-5002
VL - 31
SP - 163
EP - 170
JO - Lung Cancer
JF - Lung Cancer
IS - 2-3
ER -
